A Journal Scan supplement to Clinical Endocrinology News. This supplement was sponsored by Daiichi Sankyo, Inc.
• Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A Randomized, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Effect of Colesevelam Hydrochloride on Glycemic Control in Subjects with Type 2 Diabetes
• Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy
• Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
• Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin: Glucose and Lipid Effects
Harold E. Bays, MD, FACP, FACE
Louisville Metabolic and
Atherosclerosis Research Center
Dr Bays has research grants, consultant fees, and speaker fees with Abbott Laboratories, Aegerion Pharmaceuticals, Akros Pharma Inc, Amarin, Amgen Inc., Amylin Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Arete Therapeutics Inc., AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Corporation, Cargill, Inc., Daiichi Sankyo, Inc., Eli Lilly and Company, Essentialis, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Inc., Home Access Health Corporation, InteKrin Therapeutics Inc., Isis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc.,Merck/Schering-Plough Pharmaceuticals, Metabolex, Inc., Neuromed Pharmaceuticals Ltd., NicOx, Novo Nordisk A/S, Orexigen Therapeutics, Inc., Pfizer Inc., Purdue Pharma L.P., sanofi-aventis US LLC, Sciele Pharma, Inc., Surface Logix, Inc., Takeda Pharmaceutical Company Limited, and VIVUS Inc.
Peter H. Jones, MD
Associate Professor of Medicine
Baylor College of Medicine
Dr Jones has consulting agreements with Abbott Laboratories, AstraZeneca, Daiichi Sankyo, Inc., and Merck/Schering-Plough Pharmaceuticals.
Copyright © 2010 Elsevier Inc.